By Colin Kellaher


Johnson & Johnson's Janssen Pharmaceutical Cos. unit and Legend Biotech Corp. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of their cell-based therapy Carvykti for certain patients with the blood cancer multiple myeloma.

The companies said the recommendation covers Carvykti for the treatment of adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and have shown disease progression on the last therapy.

Janssen and Legend, a Somerset, N.J.-based biotechnology company, in late 2017 struck an exclusive world-wide license and collaboration agreement to develop and commercialize Carvykti.

The U.S. Food and Drug Administration last month approved Carvykti, making it the first customized, cell-based treatment in the U.S. to be developed initially in China.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

03-25-22 0834ET